Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition to pancreaticobiliary, appendiceal and colonic tumours, SMAD4 loss is also seen in a small subset of other carcinomas, specifically breast, lung, oesophageal and gastric adenocarcinomas, all of which are typically CK7-positive, similar to pancreaticobiliary carcinoma.
|
31054158 |
2019 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Pancreatic ductal adenocarcinomas with SMAD4 loss also had lower disease-specific survival (P = 0.041) and metastasis-free survival (P = 0.001) than those with intact SMAD4.
|
30683911 |
2019 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Correspondence between mutation sites and morphology was demonstrated directly in a mixed adenocarcinoma and neuroendocrine tumor where SMAD4 mutations involving different protein domains were found in histologically disparate tumor regions despite both containing identical KRAS and TP53 mutations.
|
30730996 |
2019 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
|
28053288 |
2017 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Among these, Smad4 mutation is relatively specific and its inactivation is found in more than 50% of invasive pancreatic adenocarcinomas.
|
28067794 |
2017 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Combination immunohistochemistry for SMAD4 and Runt-related transcription factor 3 may identify a favorable prognostic subgroup of pancreatic ductal adenocarcinomas.
|
29100342 |
2017 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
KRAS mutational and SMAD4/DPC4 immunohistochemical studies can discriminate between adenocarcinoma derived from HP and concurrent adenocarcinoma with HP.
|
28368927 |
2017 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Using genetically engineered mouse models, we show that heterozygous mutation of Dpc4/Smad4 attenuates the metastatic potential of Kras(G12D/+);Trp53(R172H/+) pancreatic ductal adenocarcinomas while increasing their proliferation.
|
26004068 |
2015 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
NGS of routine biopsy samples from an exceptional non-responder identified SMAD4 as a driver of the aggressive course and supports derivation of NePC from primary adenocarcinoma (transdifferentiation).
|
26444865 |
2015 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Mutations in KRAS, P16/CDKN2A, TP53, and SMAD4/DPC4 are commonly seen in ductal neoplasia but not in nonductal tumors; ductal adenocarcinomas with SMAD4/DPC4 loss are associated with widespread metastasis and poor prognosis.
|
24436263 |
2014 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of ANXA10 (P = .038), SMAD family member 4 (P = .028), and deleted in colorectal carcinoma (P = .004) was less common in adenocarcinoma of the distal stomach than in adenocarcinoma of the gastric cardia.
|
22901464 |
2012 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of a dominant-negative Smad4 construct in the adenocarcinoma cell line PANC-1 led to increased ubiquitination and proteasomal degradation of beta-catenin.
|
18310088 |
2008 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
TP53 and SMAD4 status were determined by immunohistochemistry on tissue microarrays of 23 archival familial pancreatic adenocarcinomas and in selected cases by cycle sequencing to identify TP53 gene mutations.
|
19064568 |
2008 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Resected pancreatic ductal and ampullary adenocarcinomas (n = 50) were analyzed for loss of heterozygosity (LOH) at 15 markers including 5q(APC), 6q(TBSP2), 9p(p16), 10q(PTEN), 12q(MDM2), 17p(TP53), and 18q(DCC/SMAD4).
|
18677542 |
2008 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The regional and intense positive cases of DPC4 expression in adenocarcinoma detected by immunohistochemistry were 10 and four, whereas it was all positive expression in normal tissues.
|
18985820 |
2008 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
LHGDN |
The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors.
|
17854080 |
2007 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of SMAD4 was investigated in 283 gastric adenocarcinomas and related lesions, as well as in 9 gastric carcinoma cell lines.
|
17200344 |
2007 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As a whole, about 50% of the Por tumors and 80% of the Sig tumors showed abnormalities of either TGF-beta RII or SMAD4 expression.
|
17167985 |
2006 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Smad4 protein expression correlates with grade, stage, and DNA ploidy in prostatic adenocarcinomas.
|
16260274 |
2005 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in Smad4/DPC4 have been identified in approximately 50% of pancreatic adenocarcinomas.
|
15855639 |
2005 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted.
|
15736060 |
2005 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Also, higher Smad4 protein expression in intestinal type gastric adenocarcinomas than overall gastric adenoma was noted.
|
15736060 |
2005 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
LHGDN |
Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.
|
15367885 |
2004 |
Adenocarcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The presence of chromosome 18q loss and DPC4 mutations in appendiceal adenocarcinomas suggests involvement of DPC4 and nearby genes on chromosome 18q (DCC and/or JV-18) in the pathogenesis of appendiceal adenocarcinomas.
|
14647445 |
2004 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
LHGDN |
In conclusion, our data suggest a significant role of impaired SMAD4 function in the pathogenesis of small intestinal adenocarcinomas.
|
15157044 |
2004 |